Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF)
OTCMKTS · Delayed Price · Currency is USD
5.20
+2.19 (72.76%)
At close: Nov 7, 2025

RAJAF Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.251.250.880.05-
Revenue Growth (YoY)
-0.65%42.03%1555.66%--
Cost of Revenue
0.480.720.120.01-
Gross Profit
0.760.530.770.04-
Selling, General & Admin
0.90.720.540.340.09
Research & Development
---0.120.03
Operating Expenses
0.90.720.540.450.12
Operating Income
-0.14-0.180.23-0.42-0.12
Interest Expense
-0.02-0.02-0.04--
Interest & Investment Income
---00
Other Non Operating Income (Expenses)
0.010.010--
EBT Excluding Unusual Items
-0.15-0.20.19-0.42-0.12
Gain (Loss) on Sale of Assets
-0---
Pretax Income
-0.15-0.190.19-0.42-0.12
Income Tax Expense
-0.030.02--
Earnings From Continuing Operations
-0.15-0.230.17-0.42-0.12
Earnings From Discontinued Operations
--0.58-0.3-0.37
Net Income
-0.15-0.230.75-0.72-0.49
Net Income to Common
-0.15-0.230.75-0.72-0.49
Shares Outstanding (Basic)
111111111104100
Shares Outstanding (Diluted)
111111111104100
Shares Change (YoY)
--6.42%4.42%-
EPS (Basic)
-0.00-0.000.01-0.01-0.00
EPS (Diluted)
-0.00-0.000.01-0.01-0.00
Free Cash Flow
-0.04-0.040.04-0.32-0.47
Free Cash Flow Per Share
----0.00-0.01
Gross Margin
61.09%42.58%86.84%74.21%-
Operating Margin
-11.33%-14.67%25.82%-778.78%-
Profit Margin
-12.43%-18.05%85.17%-1350.92%-
Free Cash Flow Margin
-2.88%-2.97%4.56%-602.91%-
EBITDA
0.070.240.28-0.390.03
EBITDA Margin
5.47%19.16%32.25%--
D&A For EBITDA
0.210.420.060.020.15
EBIT
-0.14-0.180.23-0.42-0.12
EBIT Margin
-11.33%-14.67%25.82%--
Effective Tax Rate
--11.28%--
Revenue as Reported
1.251.250.880.05-